The diagnostic and prognostic value of LncRNA FAM3D-AS1 expression in nasopharyngeal carcinoma and its effect on tumor progression and cisplatin resistance.

Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 0374654 Publication Model: Electronic Cited Medium: Internet ISSN: 1601-5223 (Electronic) Linking ISSN: 00180661 NLM ISO Abbreviation: Hereditas Subsets: MEDLINE

Publication: Oct. 2015- : London : BioMed Central Ltd.
Original Publication: Lund : Mendelska sällskapet.

RNA, Long Noncoding*/genetics ; Cisplatin*/pharmacology ; Cisplatin*/therapeutic use ; Nasopharyngeal Carcinoma*/genetics ; Nasopharyngeal Carcinoma*/diagnosis ; Nasopharyngeal Carcinoma*/drug therapy ; Nasopharyngeal Carcinoma*/pathology ; Drug Resistance, Neoplasm*/genetics ; Nasopharyngeal Neoplasms*/genetics ; Nasopharyngeal Neoplasms*/drug therapy ; Nasopharyngeal Neoplasms*/diagnosis; Humans ; Male ; Female ; Prognosis ; Middle Aged ; Cell Line, Tumor ; Adult ; Disease Progression ; Gene Expression Regulation, Neoplastic ; Biomarkers, Tumor/genetics ; ROC Curve ; Antineoplastic Agents/pharmacology ; Kaplan-Meier Estimate

Competing Interests: Declarations. Ethics approval and consent to participate: The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Xianning Central Hospital before the study began. The written informed consent has been obtained from the participants involved. Every human participant provided their consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Consent to participate: Not applicable.
Background: The location of nasopharyngeal carcinoma (NPC) is relatively hidden. Most patients are diagnosed at the middle or late stage of the disease, having missed the best time for treatment.
Aim: To explore the clinical value of lncRNA FAM3D-AS1 and its effect on tumor progression and cisplatin resistance in nasopharyngeal cancer.
Materials and Methods: In this study, a total of 118 NPC patients and 50 healthy volunteers participated. RT-qPCR was analyzed to detect the lncRNA FAM3D-AS1 expression in NPC patients and cells. Receiver Operating Characteristic (ROC curves), Kaplan-Meier (K-M) survival curves and Cox regression analysis were performed to analyze the clinical value value of lncRNA FAM3D-AS1. Cell functional assays were employed to investigate the impact of lncRNA FAM3D-AS1 on biological malignant behavior of NPC and cisplatin resistance.
Results: In NPC patients' serum and cell lines, the expression of lncRNA FAM3D-AS1 was upregulated. ROC curves with Area Under the Curve (AUC) = 0.920, 95%CI = 0.874-0.965 could be used to distinguish the healthy group from the NPC group. K-M survival curves revealed that NPC patients with high expression of lncRNA FAM3D-AS1 had poor prognosis. Cox regression analysis suggested that lncRNA FAM3D-AS1 was an independent prognostic marker for NPC. Knockdown of lncRNA FAM3D-AS1 expression prohibited NPC cell proliferation, migration, invasion, and cisplatin resistance, but promoted apoptosis.
Conclusion: LncRNA FAM3D-AS1 can be used as a biomarker to diagnose and prognosticate NPC. LncRNA FAM3D-AS1 affects tumor progression and cisplatin resistance in NPC.
(© 2025. The Author(s).)

Cancer Metastasis Rev. 2024 Sep;43(3):919-939. (PMID: 38430391)
Cell Death Differ. 2022 Aug;29(8):1513-1527. (PMID: 35105963)
Clin Chem Lab Med. 2019 Jun 26;57(7):1063-1072. (PMID: 30763257)
J Exp Clin Cancer Res. 2022 Feb 24;41(1):77. (PMID: 35209949)
Biomarkers. 2019 Dec;24(8):735-738. (PMID: 31587591)
Biomed Rep. 2024 Aug 05;21(4):143. (PMID: 39161943)
Front Immunol. 2024 Feb 22;15:1327281. (PMID: 38455041)
JAMA Oncol. 2024 Sep 1;10(9):1292. (PMID: 38990550)
Clin Transl Med. 2023 Sep;13(9):e1361. (PMID: 37658588)
Ann Hepatol. 2021 Jul-Aug;23:100297. (PMID: 33346094)
BMC Cancer. 2022 Mar 29;22(1):343. (PMID: 35351056)
Front Immunol. 2022 Mar 02;13:845418. (PMID: 35309319)
Front Immunol. 2022 Mar 03;13:844778. (PMID: 35309316)
Lancet. 2019 Jul 6;394(10192):64-80. (PMID: 31178151)
Cancer Commun (Lond). 2018 Sep 3;38(1):55. (PMID: 30176932)
Acta Biochim Biophys Sin (Shanghai). 2023 Feb 25;55(4):649-660. (PMID: 36786074)
Drug Resist Updat. 2024 Sep;76:101111. (PMID: 38908233)
Int J Biol Macromol. 2024 Dec;283(Pt 4):137809. (PMID: 39577524)
Onco Targets Ther. 2019 Jun 12;12:4509-4516. (PMID: 31354286)
Cancer Cell Int. 2019 May 22;19:141. (PMID: 31139018)
Cancer Treat Rev. 2019 Sep;79:101890. (PMID: 31470314)
Exp Mol Pathol. 2019 Jun;108:89-96. (PMID: 30953646)
Neoplasia. 2024 Oct;56:101034. (PMID: 39128424)
Bioengineered. 2022 Apr;13(4):11026-11041. (PMID: 35475392)
EBioMedicine. 2021 Aug;70:103522. (PMID: 34391094)
Cell Death Dis. 2021 Feb 1;12(2):137. (PMID: 33542203)
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188502. (PMID: 33428963)
Cancer Biother Radiopharm. 2022 May;37(4):246-255. (PMID: 32935999)
Front Immunol. 2023 Jan 11;13:1079515. (PMID: 36713430)
Open Med (Wars). 2023 Mar 30;18(1):20230673. (PMID: 37016706)
Anticancer Res. 2022 Jul;42(7):3507-3522. (PMID: 35790268)
Int J Biol Macromol. 2022 Dec 1;222(Pt B):1676-1687. (PMID: 36179873)
Cell Mol Biol Lett. 2023 Jul 7;28(1):53. (PMID: 37420173)

Keywords: Cisplatin resistance; Diagnosis; LncRNA FAM3D-AS1; Nasopharyngeal carcinoma; Prognosis

0 (RNA, Long Noncoding)
Q20Q21Q62J (Cisplatin)
0 (Biomarkers, Tumor)
0 (Antineoplastic Agents)

Date Created: 20250827 Date Completed: 20250827 Latest Revision: 20250829

20250903

PMC12379458

10.1186/s41065-025-00526-0

40859288